Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ProMetic Life Sciences has announced that it will launch fibrinogen for commercial sales during the fourth quarter of 2014 after its successful scale-up at its Laval based plasma purification facility, ProMetic BioProduction Inc. (PBP).
Subscribe to our email newsletter
This follows the previously disclosed proteins already scheduled for production at PBP, namely plasminogen, IVIG and Alpha-1 Antitrypsin.
Sales of fibrinogen manufactured at commercial scale to pharmaceutical companies as a GMP product will be starting in the fourth quarter of 2014, 6 months ahead of the originally anticipated timeline.
The fibrinogen protein has many commercial applications ranging from harvesting and culturing stem cells to use in wound healing products, hemostatic bandages and drug delivery systems. The worldwide market for fibrinogen exceeds $500 million per year. The Corporation is already in discussion with potential users of the product about making initial supplies in the fourth quarter of 2014.
"There is a growing market for fibrinogen used in various commercial applications that do not require regulatory authorization and we expect revenue contribution to start as soon as the fourth quarter 2014", said Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic who also added "We are also considering a clinical regulatory pathway to support the use of fibrinogen for specific rare and unmet medical conditions".
ProMetic’s proprietary and proven PPPS platform has consistently delivered higher recovery yield for several proteins, including fibrinogen which has a production yield exceeding double that of the industry average. Prometic is also further leveraging its PPPS platform to enable the manufacturing of two other orphan drugs in 2014.